AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.
David Spigel, MD
Advertisement
David Spigel, MD, is the president and chief medical officer of Sarah Cannon Research Institute.
Articles by David Spigel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
4
Tavapadon for Parkinson Disease Approved by FDA
5